Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04351243 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
A Phase 2 study of COVID-19, sponsored by Kinevant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
- 20
- Study locations
NCT04351243 is a Phase 2 study of COVID-19 that has completed, run by Kinevant Sciences. The registered enrollment target is 227 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04351243, a Phase 2 study of COVID-19, has completed, sponsored by Kinevant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to COVID-19.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gimsilumab
Study Locations (20)
Arizona
- Banner University Medical Center - Phoenix
- HonorHealth John C. Lincoln Medical Center - Phoenix
- HonorHealth Scottsdale Osborn Medical Center - Scottsdale
- HonorHealth - Scottsdale
- HonorHealth Scottsdale Shea Medical Center - Scottsdale
- Banner University Medical Center - Tucson
New York
- Jamaica Hospital Medical Center - Jamaica
- Mount Sinai Beth Israel - New York
- Mount Sinai West - New York
- Mount Sinai Morningside - New York
- Icahn School of Medicine at Mount Sinai - New York
Florida
- University of Florida - Gainesville
- Miami Cancer institute - Miami
Georgia
- Piedmont Healthcare - Atlanta
- Emory University School of Medicine - Atlanta
California
- UCLA Ronald Reagan Medical Center - Los Angeles
Illinois
- NorthShore University HealthSystem - Evanston
Louisiana
- East Jefferson General Hospital - Metairie
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2020-04-15 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04351243
The ClinicalTrials.gov registry entry for NCT04351243 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Kinevant Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04351243 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Arizona, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT04351243 about?
NCT04351243 is a clinical study titled "A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)". Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to COVID-19.
What is the current status of trial NCT04351243?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2020-04-15. Estimated completion is 2021-04-01.
What conditions does trial NCT04351243 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04351243?
The interventions under investigation include: Placebo (DRUG), Gimsilumab (DRUG).
Who is sponsoring clinical trial NCT04351243?
This trial is sponsored by Kinevant Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04351243 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.